The effects of the monoamine stabilizer (−)-osu6162 on binge-like eating and cue-controlled food-seeking behavior in rats

ABSTRACT Binge-eating disorder (BED) is characterized by recurring episodes of excessive consumption of palatable food and an increased sensitivity to food cues. Patients with BED display an

addiction-like symptomatology and the dopamine system might be a potential treatment target. The clinically safe monoamine stabilizer (−)-OSU6162 (OSU6162) restores dopaminergic dysfunction

in long-term alcohol-drinking rats and shows promise as a novel treatment for alcohol use disorder. Here, the effects of OSU6162 on consummatory (binge-like eating) and appetitive

(cue-controlled seeking) behavior motivated by chocolate-flavored sucrose pellets were evaluated in non-food-restricted male Lister Hooded rats. OSU6162 significantly reduced binge-like

intake of chocolate-flavored sucrose pellets without affecting prior chow intake. Furthermore, OSU6162 significantly reduced the cue-controlled seeking of chocolate-flavored sucrose pellets

under a second-order schedule of reinforcement before, but not after, the delivery and ingestion of reward, indicating a selective effect on incentive motivational processes. In contrast,

the dopamine D2/D3 receptor antagonist raclopride reduced the seeking of chocolate-flavored sucrose pellets both pre- and post reward ingestion and also reduced responding under simpler

schedules of seeking behavior. The D1/5 receptor antagonist SCH23390 had no effect on instrumental behavior under any reinforcement schedule tested. Finally, local administration of OSU6162

into the nucleus accumbens core, but not dorsolateral striatum, selectively reduced cue-controlled sucrose seeking. In conclusion, the present results show that OSU6162 reduces binge-like

eating behavior and attenuates the impact of cues on seeking of palatable food. This indicates that OSU6162 might serve as a novel BED medication. SIMILAR CONTENT BEING VIEWED BY OTHERS THE

MONOAMINE STABILIZER OSU6162 HAS ANXIOLYTIC-LIKE PROPERTIES AND REDUCES VOLUNTARY ALCOHOL INTAKE IN A GENETIC RAT MODEL OF DEPRESSION Article Open access 04 June 2021 PRECLINICAL SUPPORT FOR

THE THERAPEUTIC POTENTIAL OF ZOLMITRIPTAN AS A TREATMENT FOR COCAINE USE DISORDERS Article Open access 03 August 2020 VOLUNTARY ALCOHOL INTAKE ALTERS THE MOTIVATION TO SEEK INTRAVENOUS

OXYCODONE AND NEURONAL ACTIVATION DURING THE REINSTATEMENT OF OXYCODONE AND SUCROSE SEEKING Article Open access 06 November 2023 INTRODUCTION Binge-eating disorder (BED) is characterized by

persistent uncontrollable episodes of eating large amounts of palatable food, and an increased responsivity to food-associated cues (Schienle et al, 2009) inducing food cravings and

overeating (Curtis and Davis, 2014; Sobik et al, 2005). These behaviors resemble symptoms of substance use disorders, including loss of control over drug intake, drug cue sensitivity, and

craving (Cassin and von Ranson, 2007). The mesocorticolimbic dopamine system may be implicated in the overlapping neural mechanisms between the two disorders, as well as the reinforcing

effects of both palatable foods and drugs of abuse (Gonzales et al, 2004; Wise, 2006). In fact, intake of both palatable food and drugs of abuse (Ericson et al, 1998; Ito et al, 2000; Rada

et al, 2005) and cues associated with these reinforcers (Di Ciano et al, 1998; du Hoffmann and Nicola, 2014) release dopamine in the nucleus accumbens (NAc) in rodents. Similarly, in both

BED (Wang et al, 2011) and substance use disorders (Volkow et al, 2006), dopamine is released in the striatum following the presentation of food- and drug-associated cues, respectively.

Moreover, like chronic drug intake, chronic binge-like intake of palatable food induces addictive-like behaviors and dopaminergic changes in the striatum (Avena, 2010; Naef et al, 2015),

including decreased NAc dopamine D2 receptor levels in rodents (Avena, 2007; Bello and Hajnal, 2010; Colantuoni et al, 2001). In addition, genetic studies have associated binge-eating

pathology in humans with polymorphisms of the dopamine transporter and D2 receptor (for review see Bello and Hajnal, 2010). Finally, the monoamine-releasing compound lisdexamfetamine is the

only FDA-approved BED medication (Davis and Attia, 2017). However, because of the medication’s side effects and abuse potential, improved treatment options are needed. The monoamine

stabilizer (−)-OSU6162 (OSU6162) (Sonesson et al, 1994) is a clinically safe compound (Johansson et al, 2012; Khemiri et al, 2015; Kloberg et al, 2014) with the ability to increase and

decrease dopaminergic activity depending on the prevailing dopaminergic tone (Rung et al, 2008; Tedroff et al, 1998). Instead of partial agonism, antagonism at both extrasynaptic dopamine D2

auto- and heteroreceptors (Tolboom et al, 2014) has been hypothesized to underlie this effect. We recently identified OSU6162 as a potential treatment for alcohol use disorder by showing

that it attenuates alcohol-mediated behaviors (Steensland et al, 2012) and restores striatal dopaminergic deficits (Feltmann et al, 2016) in alcohol-drinking rats, as well as attenuates

alcohol craving in alcohol-dependent humans (Khemiri et al, 2015). Based on the behavioral and neurochemical similarities between BED and substance use disorders, together with our

observation that OSU6162 reduced sucrose drinking in rats (Steensland et al, 2012), we here explored the potential of OSU6162 as a novel BED treatment using relevant rodent models. The

effect of OSU6162 on food consumption was investigated using a model of binge-like intake of highly palatable food (Cottone et al, 2008; Giuliano et al, 2012) and the ability of OSU6162 to

affect the impact of food-associated cues was investigated using food seeking under a second-order schedule of reinforcement (Giuliano et al, 2012). In the latter procedure, animals respond

on a fixed-ratio schedule (FR10) for brief, contingent presentations of reward-associated conditioned stimuli (CS), acting as conditioned reinforcers, during two 15 min intervals. Each

interval is terminated by reward delivery (20 chocolate-flavored sucrose pellets). This procedure was used to investigate whether OSU6162, compared with dopamine D1 and D2 receptor

antagonists, affects high-incentive food reward seeking directly (first interval, before reward delivery) or indirectly via alteration of the hedonic impact of food ingestion (second

interval, after reward delivery) (Giuliano et al, 2012). Furthermore, to evaluate whether potential effects would be specific to prolonged seeking and CS responding, the effects of the

compounds were also investigated under fixed interval (FI) schedules: one involving frequent reward delivery (1 min, FI1) and one similar to the second-order schedule but without contingent

CS presentations (FI15). Finally, to identify brain areas involved in mediating the systemic effects of OSU6162 on the second-order schedule, local bilateral OSU6162 infusions were given

into the NAc core and dorsolateral striatum (DLS). These two structures were targeted as they, in contrast to the NAc shell, have been consistently shown to be implicated in conditioned

reinforcement and in the effects of conditioned reinforcers on instrumental seeking behavior in a second-order schedule of reinforcement (Ito et al, 2000); for example, the integrity of the

NAc core is necessary for the expression of conditioned reinforcement and the acquisition of a novel response for a food- or cocaine-paired conditioned reinforcer (Di Ciano, 2008; Di Ciano

and Everitt, 2004; Parkinson et al, 1999). MATERIALS AND METHODS Detailed descriptions of animals (male Lister Hooded rats (Charles River, Margate, UK)), housing conditions, intracranial

guide cannula implantation and drug infusion, histological assessment of cannula placement, and drugs and chemicals are available in Supplementary Information. All procedures were conducted

according to the UK Animal (Scientific Procedures) Act 1986 Amendment Regulations 2012, following ethical review by the University of Cambridge Animal Welfare and Ethical Review Body

(AWERB). BINGE-LIKE EATING OF HIGHLY PALATABLE FOOD PARADIGM The binge-eating procedure was used to induce a binge-like hyperphagia of palatable food and a prior chow hypophagia in

anticipation of the palatable food (negative anticipatory contrast). The procedure was performed as described previously (Cottone et al, 2008; Giuliano et al, 2012) but minor modifications

were made. In brief, male rats with free access to rodent chow in the home cage throughout the experiment were transferred daily to behavioral chambers. After 2 h of food deprivation, rats

had access to chow in one (first) and then another (second) feeder for 10 min in each feeder. After 20 sessions rats were divided into two groups, both of which had access to chow from the

first feeder and chocolate-flavored sucrose pellets (chow/sucrose group, _n_=10) or chow (chow/chow group, _n_=10) from the second feeder, respectively (Figure 1a). TREATMENT To ensure

binge-like eating in the chow/sucrose group, testing began at least 15 sessions after the chocolate-flavored sucrose pellets had been introduced in the second feeder (Figure 1a). Thereafter,

OSU6162 (5, 10, 15, and 30 mg/kg, subcutaneously (i.p.)) or vehicle were administered 60 min before giving access to the first feeder using a Latin square design with 2 days of

re-baselining in between injections. One rat in the binge-eating paradigm was excluded from analysis because of ill health. SEEKING OF HIGHLY PALATABLE FOOD: SECOND-ORDER SCHEDULE OF

REINFORCEMENT PARADIGM The second-order schedule of high-incentive food reinforcement procedure was performed as previously described (Giuliano et al, 2012), except that rats in the present

experiment were given unlimited access to food in the home cages throughout the experiment. Briefly, 24 rats were initially trained in operant chambers to press a lever under a FR1 schedule

for delivery of chocolate-flavored sucrose pellets, paired with a 20 s light stimulus (CS). Following five sessions on FR1 (Figure 1b), sessions under FI schedules were introduced during

which pellet delivery and 20 s CS presentation was restricted to the first lever press after the end of each 1 min interval (FI1). After ∼15 sessions on FI1, the length of the intervals was

progressively increased up to 15 min (FI15) during six sessions (FI2, FI4, FI6, FI8, FI10, and FI15), whereas the maximum total number of 40 pellets/session remained constant (ie, during a

FI15 session, 20 pellets were delivered together with a 20 s CS at the end of each of the two intervals). Following 13 sessions on FI15, a second-order schedule of reinforcement was

introduced, differing only from the FI15 schedule in the presentation of a brief 1 s CS together with every tenth lever press during each interval. Pellet consumption was assessed by

checking for any remaining pellets in the food tray at the end of each session. TREATMENT The animals were divided into three groups (matched for baseline FI1 responding, _n_=8 per group)

and treated with OSU6162 (5, 10, and 15 mg/kg, s.c.), raclopride (0.01, 0.03, and 0.1 mg/kg, s.c.), or SCH23390 (0.003, 0.01, and 0.03 mg/kg, intraperitoneally (i.p.)), respectively. Testing

was conducted within each treatment group after reaching stable baseline performance on FI1, FI15, and second-order schedules, respectively, using a Latin square design within each schedule

with at least 2 days of rebaselining in between injections. SURGICAL PROCEDURES AND INTRACEREBRAL INFUSIONS Two cohorts of rats trained on the second-order schedule of reinforcement (Figure

1c) were implanted bilaterally with guide cannulae above the NAc core (AP +1.7, ML ±1.9, DV –1.5) or DLS (AP +1.2, ML ±3.0, DV −2.0). The first cohort was the same as in the previous

experiment (systemic injections of OSU6162, raclopride, or SCH23390); surgery took place within 2 weeks after the last injection on the second-order schedule. The second group was prepared

using a similar training procedure with the exception of shorter FI1 and FI15 schedules as no drug testing was conducted. OSU6162 (0.5, 1.5, and 5 μg/0.5 μl/side, Latin square design) was

bilaterally infused into the NAc core or DLS 5 min before the start of the session. Only animals with cannula placements in the target areas were included in the statistical analysis (see

details in Supplementary Information). STATISTICAL ANALYSIS To identify overall effects on acquisition of the binge-like eating behavior, food intake (kcal) was analyzed using

repeated-measures analysis of variance (ANOVA) with diet (group: chow/chow, chow/sucrose) as the between-subject factor and day and feeder as within-subject factors. Significant main effects

of diet were followed by repeated-measures ANOVA with day and feeder as within-subject factors for each diet group separately. Significant feeder × session interactions were followed by

repeated-measures ANOVA within each feeder. A significant main effect of day was followed by Sidak _post hoc_ to evaluate significant changes against day 1. To detect overall effects of

OSU6162 treatment in the binge-like eating model, food intake (kcal) was analyzed using repeated-measures ANOVA with diet group as the between-subject factor and feeder and treatment as

within-subject factors. Upon confirmation of a significant main effect of diet, repeated-measures ANOVA with treatment and feeder as within-subject factors were performed for each diet group

separately and significant feeder × treatment interactions were followed by repeated-measures ANOVA within each feeder. Significant main effect of treatment was followed by within-subject

contrasts to vehicle. Effects of systemic and intracerebral drug treatments on operant food seeking under FI1, FI15, and second-order schedules were analyzed using separate one-way

repeated-measures ANOVAs for each drug and schedule as well as within each 15 min interval. Data of the FI15 and second-order schedule were not normally distributed and therefore square root

transformed before analysis. Note that the non-transformed number of lever presses is presented in the figures for the sake of clarity. Significant treatment effects were followed by

within-subject contrasts to vehicle. Statistical analyses were performed using the software SPSS (version 22, Chicago, IL) and all values were reported as mean±SEM. The significance level

was set at _α_⩽0.05. RESULTS BINGE-LIKE EATING IS INDUCED BY LIMITED ACCESS TO CHOCOLATE-FLAVORED SUCROSE PELLETS A binge-like eating pattern (ie, escalation of sucrose intake over time) was

achieved by giving rats daily exposure to the following paradigm during 15 days of training: 2 h food deprivation, 10 min access to chow in the first feeder, followed by a 10 min access to

either chow (chow/chow group) or chocolate-flavored sucrose pellets (chow/sucrose group) in the second feeder. There were significant overall main effects of diet group (ie, chow/chow _vs_

chow/sucrose; F1, 17=118.3, _p_<0.001), session (F14, 238=18.6, _p_<0.001), and feeder (F1, 17=100.6, _p_<0.001), as well as a diet × session × feeder interaction (F14, 238=17.9,

_p_<0.001). Within-group analyses revealed significant session × feeder interactions in both diet groups (chow/chow: F14, 112=2.9, _p_<0.01; chow/sucrose: F14, 126=42.5, _p_<0.001).

In the chow/chow group (Figure 2a) there was a stable chow intake in both feeders during the 15 sessions. The _post hoc_ analysis revealed that the chow/sucrose group significantly

increased the sucrose consumption to binge-like levels on each session compared with the first session (Figure 2b) and significantly decreased the chow intake starting from session 6, ie,

they displayed an anticipatory negative contrast effect, undereating the first presented food in expectation of access to the more highly preferred chocolate-flavored sucrose pellets

(Giuliano et al, 2012). Sucrose intake was similar to the binge-like levels previously reported in female Lister Hooded (Giuliano et al, 2012) and Wistar rats (Cottone et al, 2008). OSU6162

REDUCED BINGE-LIKE EATING OF CHOCOLATE-FLAVORED SUCROSE PELLETS OSU6162 significantly reduced binge-like intake of chocolate-flavored sucrose pellets, but did not significantly affect the

negative anticipatory contrast. The effect of OSU6162 (5, 10, 15, and 30 mg/kg, s.c.) on binge-like eating was evaluated after 15 sessions in the binge-eating paradigm. OSU6162 treatment

significantly affected food intake, as indicated by a significant main effect of treatment (F4, 48=16.2, _p_<0.001), and also affected food intake differently in each diet group,

depending on the feeder, as indicated by significant main effects of diet group (F1, 17=227.8, _p_<0.001), feeder (F1, 17=144.5, _p_<0.001), and a diet group × treatment × feeder

interaction (F3.3, 56.8=16.5, _p_<0.001). In the chow/chow group (Figure 2c), there was a significant main effect of treatment (F4, 32=7.7, _p_<0.001) but no feeder × treatment

interaction (F4, 32=0.9, NS). Hence, analyzing both feeders together, within-subject contrast to vehicle revealed that OSU6162 at 10 (_p_<0.05) and 30 mg/kg (_p_<0.001) significantly

reduced chow intake. In the chow/sucrose group (Figure 2d), there was a significant main effect of treatment (F4, 36=9.7, _p_<0.001) and a significant feeder × treatment interaction

(F2.1, 19.1=22.9, _p_<0.001). Within-subject contrasts to vehicle for each feeder revealed that 15 and 30 mg/kg OSU6162 significantly reduced sucrose, but did not significantly affect

chow intake. Hence, there was no significant effect of OSU6162 on the anticipatory negative contrast. OSU6162 REDUCED CUE-CONTROLLED SEEKING FOR CHOCOLATE-FLAVORED SUCROSE PELLETS The

effects of OSU6162 (5, 10, and 15 mg/kg, s.c.), raclopride (0.01, 0.03, and 0.1 mg/kg, s.c.), and SCH23390 (0.003, 0.01, and 0.03 mg/kg, i.p.) were evaluated on seeking behavior motivated by

chocolate-flavored sucrose pellets under the second-order schedule of reinforcement and during prior training stages (FI1 and FI15). OSU6162 treatment significantly affected seeking

behavior under the second-order schedule (Figure 3a) during the first interval (before sucrose ingestion) (F3, 21=4.1, _p_<0.05), but not during the second interval (after sucrose

ingestion) (F3, 21=1.1, NS). Within-subject contrasts to vehicle revealed that OSU6162 (15 mg/kg) significantly reduced the responding on the active lever during the first interval only,

before delivery of food. Under the FI15 schedule (Figure 3b), OSU6162 treatment produced an overall main effect during the first (F3, 21=3.3, _p_<0.05) but not the second interval (F3,

21=1.5, NS). However, within-subject contrast to vehicle revealed no significant effects of any dose. Seeking under FI1 was not affected by OSU6162 (Figure 3c, F3, 21=2.0, NS). The

D2-receptor antagonist raclopride significantly reduced sucrose-seeking behavior under the second-order (Figure 3d, first interval: F1.4, 10.5=15.5, _p_<0.01; second interval: F3, 21=4.8,

_p_<0.05), the FI15 (Figure 3e, first interval: F3, 21=12.9, _p_<0.001; second interval: F3, 21=8.4, _p_<0.01), and the FI1 (Figure 3f, F3, 21=5.1, _p_<0.01) schedules.

Within-subject contrasts to vehicle revealed that raclopride at the highest dose (0.1 mg/kg) significantly reduced lever pressing during all schedules and both intervals. Raclopride 0.01 

mg/kg significantly reduced responding in the first interval of the second-order schedule compared with vehicle and at a dose of 0.03 mg/kg significantly reduced lever pressing during the

second interval of the FI15 schedule. SCH23390 treatment did not affect seeking behavior under either the second-order (Figure 3g, first interval: F3, 21=1.0, NS; second interval: F3,

21=0.9, NS), the FI15 (Figure 3h, first interval: F3, 21=0.2, NS; second interval: F3,21=1.7, NS), or the FI1 (Figure 3i, F3, 21=0.7, NS) schedule. None of the evaluated compounds affected

pellet consumption in any schedule compared with vehicle; all rats consumed all pellets at the end of each interval during testing. EFFECTS OF LOCAL INFUSION OF OSU6162 INTO THE NAC CORE OR

DLS ON CUE-CONTROLLED SEEKING OF CHOCOLATE-FLAVORED SUCROSE PELLETS To evaluate the involvement of the NAc core and DLS in the effects of OSU6162 on cue-controlled sucrose seeking under a

second-order schedule of reinforcement, OSU6162 (0.5, 1.5, and 5 μg/side) was bilaterally infused in either brain area before testing (Figure 4). OSU6162 infused into the NAc core (Figure

5a, _n_=15) reduced responding for sucrose in the first (before sucrose ingestion) (F3, 42=9.2, _p_<0.001) but not in the second interval (after sucrose ingestion) (F3, 42=1.4, NS).

Within-subject contrasts to vehicle revealed that animals treated with OSU6162 at 1.5 and 5 μg/side significantly reduced active lever pressing in the first interval. In contrast, OSU6162

infused into the DLS (Figure 5b, _n_=14), had no effect on responding for food in either the first (F3, 39=1.4, NS) or the second interval (F3, 39=0.07, NS). DISCUSSION The monoamine

stabilizer OSU6162 reduced binge-like consumption of chocolate-flavored sucrose pellets. Moreover, systemic as well as local administration of OSU6162 into the NAc core, but not the DLS,

reduced cue-controlled seeking behavior for these pellets under a second-order schedule of reinforcement. Thus, OSU6162 affects both consummatory and appetitive behaviors of relevance to

BED. OSU6162 reduced sucrose intake in rats that had been trained to consume binge-like quantities of chocolate-flavored sucrose pellets during brief daily access in behavioral chambers.

However, OSU6162 did not significantly alter chow intake from the first feeder (before sucrose access). These results suggest that the monoamine-stabilizing effects of OSU6162 suppress

overeating of palatable food in a model of BED directly during consumption without affecting prior anticipation. Furthermore, we previously reported that another potential treatment for BED,

the selective _μ_-opioid receptor antagonist GSK1521498, decreased bingeing on chocolate-flavored sucrose pellets and increased prior chow intake, suggestive of a decreased anticipatory

negative contrast (Giuliano et al, 2012). Hence, we suggested that GSK1521498 has a specific effect on the impact of the hedonic value of the palatable food (Giuliano et al, 2012), whereas

we found no evidence for an effect on anticipatory negative contrast after OSU6162 treatment in the current study. Together, these findings could indicate that opioid mechanisms are more

important than dopamine signaling in anticipatory negative contrast or that any dopaminergic influence on this phenomenon is not blocked by OSU6162. OSU6162 reduced chow intake in the

chow/chow group (control group for the sucrose bingeing rats) in contrast to our previous study where GSK1521498 did not produce this effect (Giuliano et al, 2012). This indicates that

OSU6162 is not generally specific to palatable food and can reduce intake of bland food. This apparent discrepancy to the effects in the sucrose-bingeing rats might be because of the fact

that rats in the chow/chow group consumed higher amounts of chow from the first feeder than rats in the chow/sucrose group. These results, together with the attenuation of sucrose binge-like

eating, suggest that OSU6162 moderates intake only if the amounts of food consumed are relatively high, regardless of palatability. This suggestion is further supported by the finding that

OSU6162 attenuated binge-like eating (34±2 kcal sucrose) but did not affect sucrose consumption in the seeking procedures (40 pellets =0.15 kcal). A similar selective, decreasing effect of

OSU6162 only when the baseline is high, has previously been reported for locomotor activity (Natesan et al, 2006; Rung et al, 2008), alcohol intake (Steensland et al, 2012) and striatal

L-[11C]DOPA influx rate (Tedroff et al, 1998). The mechanisms behind the monoamine-stabilizing effects of OSU6162 are not fully understood, but there are several plausible explanations for

its effects on food intake in the present study. First, intake of palatable food, including sucrose, induces a peak in dopamine levels in the NAc, potentially coding for the motivational

value of the food (Bassareo et al, 2002; Rada et al, 2005; Wilson et al, 1995). Thus, based on our previous finding showing that OSU6162 diminishes alcohol-induced NAc dopamine output in

alcohol-naive rats (Steensland et al, 2012), we speculate that OSU6162 might attenuate this sucrose-induced dopamine peak, reducing the motivation to consume sucrose. Second, it is possible

that an OSU6162-induced increase in dopaminergic tone before food presentation might underlie the reduction in food intake. This hypothesis is supported by rodent studies showing that: (1)

OSU6162 slowly increases and maintains a stable elevated NAc dopamine output for several hours (Feltmann et al, 2016; Steensland et al, 2012); (2) optogenetically induced stable NAc dopamine

release reduces voluntary sucrose intake (Mikhailova et al, 2016); (3) the dopamine-releasing compound lisdexamfetamine attenuates binge-like eating of chocolate (Vickers et al, 2015); and

(4) the dopamine-releasing compound methylphenidate reduces food consumption in humans and rodents (Davis et al, 2012; Thanos et al, 2015). Nevertheless, further studies are needed to

elucidate the mechanism underlying the effect of OSU6162 to reduce food consumption. In the cue-controlled sucrose-seeking (second-order schedule of reinforcement) procedure, OSU6162

significantly reduced responding during the first interval (before sucrose consumption), but not the second interval (after sucrose consumption). These results indicate that OSU6162 reduced

incentive responding for the reward without affecting its hedonic value, consistent with the theory that the dopamine system is primarily involved in incentive motivation, but not hedonic

aspects of food reward (Barbano and Cador, 2007; Berridge, 2007; Kelley et al, 2002). This effect is again in contrast to our previous findings with GSK1521498, which reduced seeking during

both intervals (Giuliano et al, 2012), suggesting that _μ_-receptor antagonism attenuates both the incentive motivational and hedonic impact of palatable food reward (for a review, see

(Giuliano and Cottone, 2015). The traditional dopamine D2 receptor antagonist raclopride, in contrast to OSU6162, reduced sucrose seeking under all schedules (FI1, FI15, and second-order),

indicating that raclopride has a more general effect on seeking than OSU6162. These results indicate that although D2 dopamine receptors seem to be implicated in the effects of OSU6162 on

cue-controlled sucrose seeking, the mechanism of action might differ between OSU6162 and raclopride. Accordingly, and in contrast to traditional D2 receptor antagonists, OSU6162 does not

induce catalepsy at high (80%) striatal D2/D3 occupancies in rodents (Natesan et al, 2006; Rung et al, 2008) or primates (Ekesbo et al, 1999). Moreover, the recent finding that OSU6162

occupies a maximum of 40% of striatal D2/D3 receptors in humans led to the hypothesis that OSU6162 might preferentially antagonize extrasynaptic, relative to synaptic, D2 receptors (Tolboom

et al, 2014), potentially explaining the lack of extrapyramidal side effects (Johansson et al, 2012; Khemiri et al, 2015; Kloberg et al, 2014). Intracranial infusion of OSU6162 into the NAc

core recapitulated the systemic effects of the compound, resulting in decreased sucrose seeking under the second-order schedule of reinforcement during the first (pre-reward), but not

second, interval. The NAc core is an important site mediating the capacity of food-associated conditioned reinforcers to control seeking behavior (Parkinson et al, 1999). Specifically,

dopamine receptors within the NAc mediate sucrose seeking (Ikemoto and Panksepp, 1996), cue-induced reinstatement of food seeking (Floresco et al, 2008), and CS-dependent

Pavlovian-Instrumental Transfer (Lex and Hauber, 2008). Whereas both systemic and local treatment with OSU6162 reduced seeking under the second-order schedule of reinforcement, none of the

OSU6162 doses tested significantly reduced seeking under the FI15 schedule compared with vehicle, suggesting that OSU6162 interacts specifically with the conditioned reinforcing effects of

food-associated cues. This might be particularly important in BED, where environmental cues such as commercials or smells often induce food cravings that are alleviated by seeking and

ingestion of the food (Curtis and Davis, 2014; Sobik et al, 2005). Infusions of OSU6162 into the DLS did not affect responding under the second-order schedule of reinforcement for sucrose,

indicating that OSU6162 does not influence the stimulus-response mechanism located in this striatal domain. These results appear to be in contrast to previous studies showing that the mixed

D1/D2 receptor antagonist _α_-flupenthixol infused into the DLS reduced habitual cocaine seeking under this schedule (Belin and Everitt, 2008; Murray et al, 2012). This discrepancy might

reflect a primary involvement of D1 signaling in the DLS, although this suggestion is contradicted by the present lack of effects of systemic SCH23390 administration. Alternatively, if there

is a primary involvement of D2 signaling, this discrepancy could also reflect the suggested differences in the mechanisms of action of OSU6162 compared with traditional D2 receptor

antagonists. Nevertheless, the involvement of the DLS and the effects of dopaminergic manipulations in the DLS on food seeking under the second-order schedule require further investigation.

In conclusion, the present study demonstrates that the monoamine stabilizer OSU6162 has the ability to reduce both binge-like eating and cue-controlled food seeking in rats. Together with a

favorable side-effect profile in humans (Johansson et al, 2012; Khemiri et al, 2015; Kloberg et al, 2014), these results warrant further investigation of the potential of the monoamine

stabilizer OSU6162 as a novel treatment for BED. FUNDING AND DISCLOSURE We thank Dr Arvid Carlsson, Sahlgrenska Academy, University of Gothenburg, for generous donation of OSU6162 (supplied

to Dr Carlsson by Pfizer Pharmaceuticals Inc). These studies were financially supported by a grant from the Swedish Society of Medicine (SLS-253061) to PS and JA, and a Medical Research

Council Programme Grant (no. G1002231) to BJE. The Behavioural and Clinical Neuroscience Institute is cofunded by the Medical Research Council and the Welcome Trust. JA was supported by the

Swedish Pharmaceutical Society and the Swedish Research Council (350-2012-230). A travel grant from the Swedish Society for Medical Research enabled KF to participate in this collaboration.

PS was supported by the Swedish Research Council (2015-03525). The authors declare no conflict of interest. REFERENCES * Avena NM (2007). Examining the addictive-like properties of binge

eating using an animal model of sugar dependence. _Exp Clin Psychopharmacol_ 15: 481–491. Article  Google Scholar  * Avena NM (2010). The study of food addiction using animal models of binge

eating. _Appetite_ 55: 734–737. Article  Google Scholar  * Barbano MF, Cador M (2007). Opioids for hedonic experience and dopamine to get ready for it. _Psychopharmacology (Berl)_ 191:

497–506. Article  CAS  Google Scholar  * Bassareo V, De Luca MA, Di Chiara G (2002). Differential expression of motivational stimulus properties by dopamine in nucleus accumbens shell versus

core and prefrontal cortex. _J Neurosci_ 22: 4709–4719. Article  CAS  Google Scholar  * Belin D, Everitt BJ (2008). Cocaine seeking habits depend upon dopamine-dependent serial connectivity

linking the ventral with the dorsal striatum. _Neuron_ 57: 432–441. Article  CAS  Google Scholar  * Bello NT, Hajnal A (2010). Dopamine and binge eating behaviors. _Pharmacol Biochem Behav_

97: 25–33. Article  CAS  Google Scholar  * Berridge KC (2007). The debate over dopamine's role in reward: the case for incentive salience. _Psychopharmacology (Berl)_ 191: 391–431.

Article  CAS  Google Scholar  * Cassin SE, von Ranson KM (2007). Is binge eating experienced as an addiction? _Appetite_ 49: 687–690. Article  Google Scholar  * Colantuoni C, Schwenker J,

McCarthy J, Rada P, Ladenheim B, Cadet JL _et al_ (2001). Excessive sugar intake alters binding to dopamine and mu-opioid receptors in the brain. _Neuroreport_ 12: 3549–3552. Article  CAS 

Google Scholar  * Cottone P, Sabino V, Steardo L, Zorrilla EP (2008). Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred

food. _Neuropsychopharmacology_ 33: 524–535. Article  CAS  Google Scholar  * Curtis C, Davis C (2014). A qualitative study of binge eating and obesity from an addiction perspective. _Eat

Disord_ 22: 19–32. Article  Google Scholar  * Davis C, Fattore L, Kaplan AS, Carter JC, Levitan RD, Kennedy JL (2012). The suppression of appetite and food consumption by methylphenidate:

the moderating effects of gender and weight status in healthy adults. _Int J Neuropsychopharmacol_ 15: 181–187. Article  CAS  Google Scholar  * Davis H, Attia E (2017). Pharmacotherapy of

eating disorders. _Curr Opin Psychiatry_ 30: 452–457. Article  Google Scholar  * Di Ciano P (2008). Distinct contributions of dopamine receptors in the nucleus accumbens core or shell to

established cocaine reinforcement under a second-order schedule. _Eur Neuropsychopharmacol_ 18: 888–896. Article  CAS  Google Scholar  * Di Ciano P, Blaha CD, Phillips AG (1998). The

relation between dopamine oxidation currents in the nucleus accumbens and conditioned increases in motor activity in rats following repeated administration of d-amphetamine or cocaine. _Eur

J Neurosci_ 10: 1113–1120. Article  CAS  Google Scholar  * Di Ciano P, Everitt BJ (2004). Conditioned reinforcing properties of stimuli paired with self-administered cocaine, heroin or

sucrose: implications for the persistence of addictive behaviour. _Neuropharmacology_ 47 (Suppl 1): 202–213. Article  CAS  Google Scholar  * du Hoffmann J, Nicola SM (2014). Dopamine

invigorates reward seeking by promoting cue-evoked excitation in the nucleus accumbens. _J Neurosci_ 34: 14349–14364. Article  CAS  Google Scholar  * Ekesbo A, Torstenson R, Hartvig P,

Carlsson A, Sonesson C, Waters N _et al_ (1999). Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate

brains. _Neuropharmacology_ 38: 331–338. Article  CAS  Google Scholar  * Ericson M, Blomqvist O, Engel JA, Soderpalm B (1998). Voluntary ethanol intake in the rat and the associated accumbal

dopamine overflow are blocked by ventral tegmental mecamylamine. _Eur J Pharmacol_ 358: 189–196. Article  CAS  Google Scholar  * Feltmann K, Fredriksson I, Wirf M, Schilstrom B, Steensland

P (2016). The monoamine stabilizer (-)-OSU6162 counteracts downregulated dopamine output in the nucleus accumbens of long-term drinking Wistar rats. _Addict Biol_ 21: 438–449. Article  CAS 

Google Scholar  * Floresco SB, McLaughlin RJ, Haluk DM (2008). Opposing roles for the nucleus accumbens core and shell in cue-induced reinstatement of food-seeking behavior. _Neuroscience_

154: 877–884. Article  CAS  Google Scholar  * Giuliano C, Cottone P (2015). The role of the opioid system in binge eating disorder. _CNS Spectr_ 20: 537–545. Article  Google Scholar  *

Giuliano C, Robbins TW, Nathan PJ, Bullmore ET, Everitt BJ (2012). Inhibition of opioid transmission at the mu-opioid receptor prevents both food seeking and binge-like eating.

_Neuropsychopharmacology_ 37: 2643–2652. Article  CAS  Google Scholar  * Gonzales RA, Job MO, Doyon WM (2004). The role of mesolimbic dopamine in the development and maintenance of ethanol

reinforcement. _Pharmacol Ther_ 103: 121–146. Article  CAS  Google Scholar  * Ikemoto S, Panksepp J (1996). Dissociations between appetitive and consummatory responses by pharmacological

manipulations of reward-relevant brain regions. _Behav Neurosc_ 110: 331–345. Article  CAS  Google Scholar  * Ito R, Dalley JW, Howes SR, Robbins TW, Everitt BJ (2000). Dissociation in

conditioned dopamine release in the nucleus accumbens core and shell in response to cocaine cues and during cocaine-seeking behavior in rats. _J Neurosci_ 20: 7489–7495. Article  CAS  Google

Scholar  * Johansson B, Carlsson A, Carlsson ML, Karlsson M, Nilsson MKL, Nordquist-Brandt E _et al_ (2012). Placebo-controlled cross-over study of the monoaminergic stabiliser (−)-OSU6162

in mental fatigue following stroke or traumatic brain injury. _Acta Neuropsych_ 24: 266–274. Article  Google Scholar  * Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M

(2002). Opioid modulation of taste hedonics within the ventral striatum. _Physiol Behav_ 76: 365–377. Article  CAS  Google Scholar  * Khemiri L, Steensland P, Guterstam J, Beck O, Carlsson

A, Franck J _et al_ (2015). The effects of the monoamine stabilizer (-)-OSU6162 on craving in alcohol dependent individuals: a human laboratory study. _Eur Neuropsychopharmacol_ 25:

2240–2251. Article  CAS  Google Scholar  * Kloberg A, Constantinescu R, Nilsson MK, Carlsson ML, Carlsson A, Wahlstrom J _et al_ (2014). Tolerability and efficacy of the monoaminergic

stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: a double-blind cross-over study. _Acta Neuropsych_ 26: 298–306. Article  Google Scholar  * Lex A, Hauber W (2008). Dopamine

D1 and D2 receptors in the nucleus accumbens core and shell mediate Pavlovian-instrumental transfer. _Learn Mem_ 15: 483–491. Article  Google Scholar  * Mikhailova MA, Bass CE, Grinevich VP,

Chappell AM, Deal AL, Bonin KD _et al_ (2016). Optogenetically-induced tonic dopamine release from VTA-nucleus accumbens projections inhibits reward consummatory behaviors. _Neuroscience_

333: 54–64. Article  CAS  Google Scholar  * Murray JE, Belin D, Everitt BJ (2012). Double dissociation of the dorsomedial and dorsolateral striatal control over the acquisition and

performance of cocaine seeking. _Neuropsychopharmacology_ 37: 2456–2466. Article  CAS  Google Scholar  * Naef L, Pitman KA, Borgland SL (2015). Mesolimbic dopamine and its neuromodulators in

obesity and binge eating. _CNS Spectr_ 20: 574–583. Article  Google Scholar  * Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM _et al_ (2006). The dopamine

stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high _in vivo_ D2 receptor occupancy,

antipsychotic-like efficacy, and low potential for motor side effects in the rat. _J Pharmacol Exp Ther_ 318: 810–818. Article  CAS  Google Scholar  * Parkinson JA, Olmstead MC, Burns LH,

Robbins TW, Everitt BJ (1999). Dissociation in effects of lesions of the nucleus accumbens core and shell on appetitive pavlovian approach behavior and the potentiation of conditioned

reinforcement and locomotor activity by D-amphetamine. _J Neurosci_ 19: 2401–2411. Article  CAS  Google Scholar  * Rada P, Avena NM, Hoebel BG (2005). Daily bingeing on sugar repeatedly

releases dopamine in the accumbens shell. _Neuroscience_ 134: 737–744. Article  CAS  Google Scholar  * Rung JP, Rung E, Helgeson L, Johansson AM, Svensson K, Carlsson A _et al_ (2008).

Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. _J Neural Transm_ 115: 899–908. Article  CAS  Google Scholar  *

Schienle A, Schafer A, Hermann A, Vaitl D (2009). Binge-eating disorder: reward sensitivity and brain activation to images of food. _Biol Psychiatry_ 65: 654–661. Article  Google Scholar  *

Sobik L, Hutchison K, Craighead L (2005). Cue-elicited craving for food: a fresh approach to the study of binge eating. _Appetite_ 44: 253–261. Article  Google Scholar  * Sonesson C, Lin CH,

Hansson L, Waters N, Svensson K, Carlsson A _et al_ (1994). Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and

structure-activity relationships. _J Med Chem_ 37: 2735–2753. Article  CAS  Google Scholar  * Steensland P, Fredriksson I, Holst S, Feltmann K, Franck J, Schilstrom B _et al_ (2012). The

monoamine stabilizer (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens. _Biol Psychiatry_ 72: 823–831. Article  CAS  Google Scholar  *

Tedroff J, Torstenson R, Hartvig P, Sonesson C, Waters N, Carlsson A _et al_ (1998). Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates:

evidence for tone-dependent normalization of striatal dopaminergic activity. _Synapse_ 28: 280–287. Article  CAS  Google Scholar  * Thanos PK, Robison LS, Steier J, Hwang YF, Cooper T,

Swanson JM _et al_ (2015). A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior. _Pharmacol Biochem Behav_ 131: 143–153. Article  CAS  Google Scholar  * Tolboom

N, Berendse HW, Leysen JE, Yaqub M, van Berckel BN, Schuit RC _et al_ (2014). The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an

[C]Raclopride PET Study in healthy human subjects. _Neuropsychopharmacology_ 40: 472–479. Article  Google Scholar  * Vickers SP, Hackett D, Murray F, Hutson PH, Heal DJ (2015). Effects of

lisdexamfetamine in a rat model of binge-eating. _J Psychopharmacol_ 29: 1290–1307. Article  CAS  Google Scholar  * Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR _et al_

(2006). Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. _J Neurosci_ 26: 6583–6588. Article  CAS  Google Scholar  * Wang GJ, Geliebter A, Volkow ND,

Telang FW, Logan J, Jayne MC _et al_ (2011). Enhanced striatal dopamine release during food stimulation in binge eating disorder. _Obesity (Silver Spring)_ 19: 1601–1608. Article  CAS 

Google Scholar  * Wilson C, Nomikos GG, Collu M, Fibiger HC (1995). Dopaminergic correlates of motivated behavior: importance of drive. _J Neurosci_ 15 (7 Pt 2): 5169–5178. Article  CAS 

Google Scholar  * Wise RA (2006). Role of brain dopamine in food reward and reinforcement. _Philos Trans R Soc Lond B Biol Sci_ 361: 1149–1158. Article  CAS  Google Scholar  Download

references ACKNOWLEDGEMENTS We thank Dr Natalia Arias and Maria Boulos for technical assistance. AUTHOR INFORMATION Author notes * Kristin Feltmann and Chiara Giuliano: These authors

contributed equally to this work. AUTHORS AND AFFILIATIONS * Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services,

Stockholm County Council, Stockholm, Sweden Kristin Feltmann & Pia Steensland * Department of Psychology and Behavioural and Clinical Neuroscience Institute, University of Cambridge,

Cambridge, UK Chiara Giuliano, Barry J Everitt & Johan Alsiö * Department of Neuroscience, Unit of Functional Neurobiology, University of Uppsala, Uppsala, Sweden Johan Alsiö Authors *

Kristin Feltmann View author publications You can also search for this author inPubMed Google Scholar * Chiara Giuliano View author publications You can also search for this author inPubMed 

Google Scholar * Barry J Everitt View author publications You can also search for this author inPubMed Google Scholar * Pia Steensland View author publications You can also search for this

author inPubMed Google Scholar * Johan Alsiö View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Kristin Feltmann.

ADDITIONAL INFORMATION Supplementary Information accompanies the paper on the Neuropsychopharmacology website SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION (DOCX 24 KB) POWERPOINT

SLIDES POWERPOINT SLIDE FOR FIG. 1 POWERPOINT SLIDE FOR FIG. 2 POWERPOINT SLIDE FOR FIG. 3 POWERPOINT SLIDE FOR FIG. 4 POWERPOINT SLIDE FOR FIG. 5 RIGHTS AND PERMISSIONS This work is

licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s

Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the

license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Reprints and permissions ABOUT THIS ARTICLE CITE THIS

ARTICLE Feltmann, K., Giuliano, C., Everitt, B. _et al._ The Effects of the Monoamine Stabilizer (−)-OSU6162 on Binge-Like Eating and Cue-Controlled Food-Seeking Behavior in Rats.

_Neuropsychopharmacol._ 43, 617–626 (2018). https://doi.org/10.1038/npp.2017.215 Download citation * Received: 12 June 2017 * Revised: 28 August 2017 * Accepted: 06 September 2017 *

Published: 12 September 2017 * Issue Date: February 2018 * DOI: https://doi.org/10.1038/npp.2017.215 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this

content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative